TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06791798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator Hyperinflation
Description: In ventilator hyperinflation volume control mode, the ventilator will be set to eight breaths per minute, and the tidal volume will be increased to deliver hyperinflation breaths that are 15 ml/kg, as will be calculated using the predicted body weight. Tidal volume will be increased in 150-ml increments until a peak airway pressure of 40 cmH2O is achieved. Once this pressure is reached, eight mechanical breaths will be delivered to the patient. After this, the ventilator will be reset to pretreatment variables, and the patient will be rested for 30 s. The sequence will be repeated. The treatment will consist of five sets of eight ventilator hyperinflation breaths.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibrocompression
Description: Vibrocompression will be performed by the physical therapist to produce vibration and will be combined with compression of the patient's chest in the expiratory phase. Every vibrocompression will be interrupted at the end of each expiratory phase to allow free inspiration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physical Therapy Program
Description: Percussion, Postural Drainage, and Suction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physical Therapy Program
Description: Percussion, Postural Drainage, and Suction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physical Therapy Program
Description: Percussion, Postural Drainage, and Suction
Study: NCT06792253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifupinostat Hydrochloride for Injection
Description: Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Injection
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Injection
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride for Injection
Description: Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin Injection
Description: Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide Injection
Description: Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide for Injection
Description: Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin Injection
Description: Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study: NCT06778096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postnatal anxiety and depression iCBTprogram
Description: The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.
Study: NCT05715203

Intervention type: DEVICE
Intervention: Pulsotonometry
Description: Evaluation of arterial stiffness

Intervention type: DEVICE
Intervention: Pulsotonometry
Description: Evaluation of arterial stiffness
Study: NCT05477459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD tartrate
Description: LSD tartrate equivalent to 25 microgram LSD base

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with equal appearance
Study: NCT06501625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily, taken continuously throughout treatment duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (for the first 8, 21-day, cycles)
Description: 1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (for the first 8, 21-day, cycles)
Description: 1500mg intravenous (IV) infusion every 3 weeks, for a maximum of 8 (21-day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (for the first 8, 21-day, cycles)
Description: 1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine (for the first 8, 21-day, cycles)
Description: 1000 mg/m2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (for the first 8, 21-day, cycles)
Description: 25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (for the first 8, 21-day, cycles)
Description: 25 mg/m\^2 IV infusion on days 1 and 8 of every 21-day cycle, for a maximum of 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (starting from cycle 9)
Description: 1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.
Study: NCT02556411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS 13,5 mg Levonorgestrel
Description: LNG-IUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS 13,5 mg Levonorgestrel
Description: LNG-IUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
Description: Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
Study: NCT05539872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I004
Description: Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoLog
Description: Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
Study: NCT05819216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Gait training on treadmill training
Study: NCT06501625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (starting from cycle 9)
Description: 1500mg intravenous (IV) infusion every 4 weeks, starting from cycle 9. Cycles are 28 days long, starting Cycle 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib Recommended Combination Dose (RCD)
Description: RCD administered orally once daily, taken continuously throughout treatment duration
Study: NCT06540560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Pelvic Plan website
Description: Following the baseline interview, participants will receive a link to a web-based self-guided program and have access for two weeks My Pelvic Plan that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Subsequent to this, participants will then complete another brief questionnaire after a two-week interval. This questionnaire will focus on willingness to consider specific treatment modalities, credibility/expectancy for specific treatment modalities, and a brief measure assessing self-efficacy for managing symptoms.
Study: NCT05524038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound device
Description: high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound device
Description: high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: injection of 4mg dexamethasone in each block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: injection of 4mg dexamethasone in each block
Study: NCT06234917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-based neurofeedback for brain activity modulation
Description: NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG-based neurofeedback for brain activity modulation
Description: NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
Study: NCT06049238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization
Description: * Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation
Study: NCT05524038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: echogenic needle
Description: 22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: echogenic needle
Description: 22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
Study: NCT06791720

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Gatherings
Description: Participants in the social control group will have a social gathering at the participating center once weekly over the 16 weeks. They will also continue to receive the usual care offered by the centers, such as social support, and health education.
Study: NCT06049238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post facilitation stretch
Description: * Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation
Study: NCT06791720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warm-up Exercise
Description: Participants will perform mobilizing exercises of all upper and lower limb joints with music, and deep breathing exercises with music. This is a transitional phase that allows the body to adjust to the changing physiological, biomechanical, and bioenergetics demands placed on it during the conditioning or sports phase of the exercise session. Warming up also improves the range of movement and may reduce the risk of injury.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Marching
Description: Participants are trained for their attention to the rhythm of music, and perform aerobic exercises. Participants are required to select and focus on the music elements to accomplish the mental tasks, i.e. moving the body parts accordingly and accurately. Rhythmic aerobic exercise of moderate intensity involving large muscle groups and requiring little skill is recommended for all adults to improve health and cardiorespiratory functioning. Even light- to moderate-intensity exercise may be beneficial in deconditioned individuals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing Familiar Songs
Description: Participants can rest for 5 minutes by singing before the next physical exercise training regime. They will listen to a familiar song regarded as cognitively stimulating because familiar music evokes autobiographical memory. Singing is more engaging than listening and brings additional benefits by synthesizing a range of specific speech, language, respiratory control, and vital capacity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Workout
Description: Participants are asked to remember steps and sequences demonstrated by the interventionist as memory training. The exercise comprises seated upper and lower extremity exercises. Elastic bands will be used to adjust the resistance intensity. The dance will be choreographed with the beat of selected and familiar music. The movement emphasizes rhythmic and contralateral movements on both sides of the body to enhance coordination and stimulation between the left and right cerebral hemispheres.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise with Relaxing Music
Description: Participants will perform stretching exercises that can improve the range of movement in the major muscle and tendon groups. When stretching exercises following resistance training, postural stability, and balance can be improved.
Study: NCT06177730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Hospital ECPR
Description: Implementation of pre-Hospital ECPr in OHCA
Study: NCT06212388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded allogeneic γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ex-vivo expanded allogeneic γδ T cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1b
Description: Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study: NCT05765552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-Task Training
Description: Motor-cognitive dual-task exercises will be applied for 2 days a week for 8 weeks.Sessions will last for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Upper and lower extremity range of motion exercises will be applied for 8-10 repetitions for 1 set 2 times a week for 8 weeks.
Study: NCT05823792

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
Description: Non-invasive diagnosis of ileocolic intussusception by ultrasound with indication for surgery
Study: NCT04734626

Intervention type: DIAGNOSTIC_TEST
Intervention: Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence
Description: CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise

Intervention type: DIAGNOSTIC_TEST
Intervention: Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence
Description: CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
Study: NCT04764968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Abdominal s.c. administration using a multi-dose reusable pen injector
Study: NCT06791720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool Down Exercises
Description: Participants will: 1) Listen to natural sound music with a tempo of around 60 beats/minute; 2) Shake the limbs slowly; 3) Lie on the back with arms alongside the body, palms facing up, and feet slightly wider than hips, with the toes splayed out to the side. It allows for a gradual recovery of heart rate and blood pressure and the removal of metabolic end products from the muscles used during the more intense exercise phases.
Study: NCT04795856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] acetate
Description: PET Tracer
Study: NCT05243004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Nurse consultation
Description: A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions.
Study: NCT05906576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab in the treatment of Crohn's disease in children
Study: NCT05410808

Intervention type: OTHER
Intervention: Questionnaires and physical examination
Description: Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered

Intervention type: OTHER
Intervention: Questionnaire
Description: Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
Study: NCT04488757

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Allostatic Load Composite
Description: All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
Study: NCT05549726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm. CAB-LA will be a choice for at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir is a white to light pink, free-flowing, extended-release injectable suspension. CAB-LA administration will occur at health facilities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Choice Delivery Model
Description: The Dynamic Choice Delivery Model includes integrated PrEP (including CAB-LA) and PEP services at outpatient clinics, antenatal clinics, and via VHT workers in community households. The procedures for each trial include PrEP/PEP counseling and services, choice of service location, HIV testing options, option for longer PrEP refills, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, assessment of PrEP/PEP barriers and personalized actions, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care differs according to country but does not routinely offer PEP or PrEP to clients seeking services, does not offer choice of service location, HIV testing option or access to medical provider mobile phone number.
Study: NCT06791135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health and Life in Balance
Description: Health and Life in Balance is an intervention for patients 65 years and older, with 2 or more chronic diseases, and an increased care need. It involved for the patient to meet with a district nurse during 1-2 meetings to set up a care plan and then have scheduled follow-ups during 6 months. During the 1-2 meetings they went through ICAN discussion aid to discuss aspects of capacity and workload in the patient's life and healthcare. The district nurse and the patient's GP had improved communication during the intervention period.~No use of drugs or devices was part of the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Care as usual
Description: Care as usual